RecruitingPhase 2NCT06989359
Immune
IgA Nephropathy
Also known as Berger disease, IgA glomerulonephritis, mesangial IgA nephropathy
IgA Nephropathy is the most prevalent primary glomerulonephritis globally, caused by mesangial deposition of poorly galactosylated polymeric IgA1 and subsequent complement activation and immune complex formation, leading to glomerular infla
ORPHA:93024 ↗Prevalence 25 in 100,000; most common primary glomerulonephritis worldwideOnset Young adulthood (2nd-3rd decade), occasionally pediatricAutoimmune glomerulonephritis (IgA mediated)
66
studies recruiting now
as of 7 Sept 2026
279
studies registered in total
as of 7 Sept 2026
29
countries with a recruiting site
as of 7 Sept 2026
22 May 2026
most recent study posted
among recruiting studies
Recruiting trials
RecruitingPhase 2NCT07522099
Chinese Adults With Kidney Disease
RecruitingPhase 4NCT07604311
Efficacy and Safety of Nefecon on Prevention of Relapse of IgA Nephropathy
RecruitingPhase 3NCT06935357
A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN)
RecruitingPhase 2NCT07541287
A Study of JADE101 in Participants With Immunoglobulin A Nephropathy
Showing the 5 most recently updated recruiting studies, as recorded 7 Sept 2026. Live status on each study page.
See all 66 recruiting studiesWhere recruiting studies are running
Countries with at least one recruiting site among the studies above, 7 Sept 2026. Tap a country to search trials there.
Keep watching
Get an email when a new IgA Nephropathy study opens.
One email a day at most. Unsubscribe with one click.
Used only for these alerts. Privacy.
Support
Patient organisations
Registry: IgAN Registry · Join ↗. Registries connect patients to researchers and often hear about trials first.
About IgA Nephropathy
IgA Nephropathy is the most prevalent primary glomerulonephritis globally, caused by mesangial deposition of poorly galactosylated polymeric IgA1 and subsequent complement activation and immune complex formation, leading to glomerular inflammation and progressive kidney injury. Clinical presentation ranges from asymptomatic hematuria detected incidentally to nephrotic syndrome and rapidly progressive glomerulonephritis, with approximately 30-40% of patients reaching end-stage kidney disease within 20-30 years. The expanding pipeline of targeted therapies — including endothelin-angiotensin system inhibitors, BAFF/APRIL inhibitors, complement pathway blockers, and sparsentan — has made IgA nephropathy one of the most actively trialed rare kidney diseases.
Common clinical features
Macroscopic hematuria coinciding with upper respiratory infectionsPersistent microscopic hematuria with or without proteinuriaHypertensionProteinuria (variable, up to nephrotic range)Declining estimated glomerular filtration rateFlank pain during gross hematuria episodesEdema in nephrotic presentations
From Orphanet’s phenotype annotations (CC BY 4.0). Not a complete list.
Treatments being studied
3 approved treatments and 38 in clinical development, from Open Targets (CC BY 4.0). Not medical advice.
Approved: Budesonide (Aircort)Approved: Sparsentan (Filspari)Approved: Iptacopan Hydrochloride (Fabhalta)
Phase 3Iptacopan
Phase 3Icosapent
Phase 3Sibeprenlimab
Phase 3Cyclophosphamide (Cyclophosphamide)
Phase 3Finerenone (Kerendia)
Phase 3Methylprednisolone (Medrol)
Phase 3Losartan
Phase 3Sefaxersen
+ 30 more in development
Before you apply
Things trial teams commonly ask about for IgA Nephropathy. Not eligibility rules; those are set by each study.
- Kidney biopsy with Oxford classification (MEST-C score) is required by virtually all trials; ensure pathology report includes mesangial IgA deposit confirmation on immunofluorescence
- Proteinuria threshold (commonly >1 g/day or >0.5 g/g urine protein:creatinine ratio) and eGFR range (often 30-90 mL/min/1.73m2) are the primary eligibility gatekeepers; provide 24-hour urine or spot ratio from last 3 months
- Maximum-tolerated RAS blockade is a prerequisite for most trials; document ACE inhibitor or ARB dose and duration along with current blood pressure readings
Related conditions
Information, not medical advice. Trial listings are shown as recorded on ClinicalTrials.gov; whether any study is right for you is a decision for you and your clinicians, and eligibility is decided by each research team. Disease information from Orphanet (CC BY 4.0).